We hypothesize that the HNSCC PDX model became insensitive to anti-PD-1 immunotherapy alone by developing multifaceted bypassing mechanisms, upregulating MET signaling pathway in addition to amplification of EGFR. This evidence concerns the gene PDCD1 and head and neck squamous cell carcinoma.